Springbuk Unveils the 2025 Employee Health Trends Report: Key Insights into Healthcare Cost Drivers and Future Trends

January 21, 2025 11:45 PM AEDT | By EIN Presswire

Google News:

Springbuk Unveils the 2025 Employee Health Trends Report: Key Insights into Healthcare Cost Drivers and Future Trends — Image source: EIN Presswire

Recent News

ASX 200 Live: Santos and Lithium Movers Shape Monday's Trading Session

Cannindah Resources (ASX:CAE) Uncovers Major Expansion Potential at Mt...

ASX 300: Syntara Sees Stake Exit by US Fund Amid Myelofibrosis Trial P...

ASX 200 Edges Lower as Geopolitical Unrest Sparks Broad-Sector Retreat

INDIANAPOLIS , IN, UNITED STATES, January 21, 2025 /EINPresswire.com/ -- Springbuk, the leading-edge health data analytics software company, today announced the release of its highly anticipated 2025 Employee Health Trends report. This in-depth analysis reflects on 25 years of healthcare evolution and provides forward-looking guidance for 2025 and beyond.

Key trends examined include:
- The evolution of employee benefits from 2000 to today and its implications for the future
- Major healthcare cost drivers and how employers can prepare
- Hidden factors behind rising prescription drug spending
- The financial challenges posed by the growing popularity of diabetes drugs like GLP-1 agonists
- The rapid rise of gastrointestinal diseases as a cost driver for employers

“Our annual Employee Health Trends report underscores Springbuk's commitment to equipping employers with the tools they need to address pressing healthcare challenges while empowering employee well-being,” said Joy Powell, CEO of Springbuk. “Powered by our unparalleled data platform and the expertise of our analysts, this year’s report offers actionable insights designed to support employers in 2025 and beyond as they navigate an increasingly complex healthcare landscape and design impactful benefits strategies.”

Key Findings:
- 2024 Healthcare Cost Surge: Another significant increase of 7.4% overall; compared to 2023, this year's trend is being impacted more equally between medical and pharmacy costs
- Prescription Drug Trends: Rx spending accounts for nearly 25% of total healthcare spend, with 2.1% of members using Rx specialty drugs driving approximately 50% of total drug costs
- Rising Diabetes Costs: PMPM for GLP-1 agonists increased nearly 42% ($6.41) in the past two years and 272% ($15.89) over the last four years, now representing approximately 16% of total Rx drug spending
- Gastrointestinal Disease Costs: GI diseases have become the third-fastest growing condition group, with total plan costs reaching $31.7 PMPM in the latest 12 months

The full 2025 Employee Health Trends Report, featuring detailed analyses, recommendations, and data visualizations, is available for download at www.springbuk.com/eht25.

About Springbuk:
Springbuk is a leading-edge health intelligence platform empowering employers and consultants to optimize their benefits strategy, advance employee health, and contain costs. Learn more at springbuk.com.

Nicole Anderson
Springbuk
+1 317-753-2264
[email protected]
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.